Literature DB >> 15556071

Plasma appearance of unesterified astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3'R/S isomers of astaxanthin fatty acyl diesters.

Gladis N Coral-Hinostroza1, Trine Ytrestøyl, Bente Ruyter, Bjørn Bjerkeng.   

Abstract

Appearance, pharmacokinetics and distribution of astaxanthin all-E-, 9Z- and 13Z-geometrical and (3R,3'R)-, (3R,3'S)- and (3S,3'S)-optical isomers in plasma fractions were studied in three middle-aged male volunteers (41-50 years) after ingestion of a single meal containing first a 10-mg dose equivalent of astaxanthin from astaxanthin diesters, followed by a dose of 100 mg astaxanthin equivalents after 4 weeks. Direct resolution of geometrical isomers and optical isomers of astaxanthin dicamphanates by HPLC after saponification showed that the astaxanthin consisted of 95.2% all-E-, 1.2% 9Z- and 3.6% 13Z-astaxanthin, of (3R,3'R)-, (3R,3'S; meso)- and (3S,3'S)-astaxanthin in a 31:49:20 ratio. The plasma astaxanthin concentration-time curves were measured during 76 h. Astaxanthin esters were not detected in plasma. Maximum levels of astaxanthin (C(max)=0.28+/-0.1 mg/l) were reached 11.5 h after administration and the plasma astaxanthin elimination half-life was 52+/-40 h. The C(max) at the low dose was 0.08 mg/l and showed that, the dose response was non-linear. The (3R,3'R)-astaxanthin optical isomer accumulated selectively in plasma compared to the (3R,3'S)- and (3S,3'S)-isomers, and comprised 54% of total astaxanthin in the blood and only 31% of total astaxanthin in the administered dose. The astaxanthin Z-isomers were absorbed selectively into plasma and comprised approximately 32% of total astaxanthin 6-7.5 h postprandially. The proportion of all-E-astaxanthin was significantly higher in the very low density lipoproteins and chylomicrons (VLDL/CM) plasma lipoprotein fraction than in the high density lipoproteins (HDL) and low denisty lipoproteins (LDL) fractions (P<0.05). The results indicate that a selective process increase the relative proportion of astaxanthin Z-isomers compared to the all-E-astaxanthin before uptake in blood and that the astaxanthin esters are hydrolyzed selectively during absorption.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15556071     DOI: 10.1016/j.cca.2004.09.011

Source DB:  PubMed          Journal:  Comp Biochem Physiol C Toxicol Pharmacol        ISSN: 1532-0456            Impact factor:   3.228


  30 in total

1.  Astaxanthin increases choroidal blood flow velocity.

Authors:  Michiyuki Saito; Kazuhiko Yoshida; Wataru Saito; Akio Fujiya; Kazuhiro Ohgami; Nobuyoshi Kitaichi; Hiroki Tsukahara; Susumu Ishida; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

2.  Milks pigmentation with astaxanthin and determination of colour stability during short period cold storage.

Authors:  Pedro Cerezal Mezquita; Blanca E Barragán Huerta; Jenifer C Palma Ramírez; Claudia P Ortíz Hinojosa
Journal:  J Food Sci Technol       Date:  2013-10-10       Impact factor: 2.701

3.  Comparison of tetrahydrofuran, fetal calf serum, and Tween 40 for the delivery of astaxanthin and canthaxanthin to HepG2 cells.

Authors:  Christine Boesch-Saadatmandi; Gerald Rimbach; Alexander Jungblut; Jan Frank
Journal:  Cytotechnology       Date:  2010-12-10       Impact factor: 2.058

Review 4.  The Putative Role of Astaxanthin in Neuroinflammation Modulation: Mechanisms and Therapeutic Potential.

Authors:  Shuai Wang; Xin Qi
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 5.  Carotenoids and cardiovascular disease.

Authors:  Graziano Riccioni
Journal:  Curr Atheroscler Rep       Date:  2009-11       Impact factor: 5.113

6.  Astaxanthin protects ARPE-19 cells from oxidative stress via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt.

Authors:  Zhongrui Li; Xin Dong; Hongling Liu; Xi Chen; Huanqi Shi; Yan Fan; Dingshan Hou; Xiaomei Zhang
Journal:  Mol Vis       Date:  2013-07-25       Impact factor: 2.367

Review 7.  Astaxanthin: a potential therapeutic agent in cardiovascular disease.

Authors:  Robert G Fassett; Jeff S Coombes
Journal:  Mar Drugs       Date:  2011-03-21       Impact factor: 5.118

Review 8.  Marine carotenoids and cardiovascular risk markers.

Authors:  Graziano Riccioni; Nicolantonio D'Orazio; Sara Franceschelli; Lorenza Speranza
Journal:  Mar Drugs       Date:  2011-06-27       Impact factor: 6.085

9.  Adonis amurensis Is a Promising Alternative to Haematococcus as a Resource for Natural Esterified (3S,3'S)-Astaxanthin Production.

Authors:  Yongfu Li; Fengying Gong; Shuju Guo; Wenjie Yu; Jianguo Liu
Journal:  Plants (Basel)       Date:  2021-05-25

10.  Astaxanthin prevents changes in the activities of thioredoxin reductase and paraoxonase in hypercholesterolemic rabbits.

Authors:  Paula R Augusti; Andréia Quatrin; Sabrina Somacal; Greicy Mm Conterato; Rocheli Sobieski; Amanda R Ruviaro; Luana H Maurer; Marta Mf Duarte; Miguel Roehrs; Tatiana Emanuelli
Journal:  J Clin Biochem Nutr       Date:  2012-06-08       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.